Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment

Pfizer

Status: Completed

Conditions: Atrial Fibrillation

Study type: Observational

Funder types: Industry

Identifiers

NCT04435769

B0661121

APIXABAN SECOND LINE (Other Identifier)

Details and patient eligibility

About

To describe the direct costs related to warfarin/apixaban treatment

Full description

To describe the direct costs related to warfarin/apixaban treatment during the first 6 months of the secondary stroke prevention in NVAF patients.

Enrollment: 109 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of non-valvular atrial fibrillation (NVAF);
• New initiation of anticoagulation therapy (apixaban or warfarin) due to the ischemic event (stroke/TIA) meaning patients previously not anticoagulated due to diagnosis of NVAF;
• Indication to anticoagulation therapy as a secondary stroke prevention within 7 to 30 days after the stroke/TIA event;
• Apixaban arm: genetically determined higher sensitivity to warfarin;
• Patients whose status allowed oral treatment with apixaban/warfarin;
• Age ≥ 18;
• Access to patient´s records of the first 6 months of the warfarin/apixaban treatment.

Exclusion criteria

• Diagnosis of valvular disease;
• Treatment with other anticoagulants in previous 6 months due to other the NVAF indication;
• Treatment or prophylaxis of deep vein thrombosis or pulmonary embolism;
• Contraindications according SmPC of Eliquis

Trial design

109 participants in 2 patient groups

Non-valvular Atrial Fibrillation (NVAF) on warfarin

Description:

The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used warfarin as a secondary stroke/TIA prevention.

Non-valvular Atrial Fibrillation (NVAF) on apixaban

Description:

The study follows two cohorts of Non-valvular Atrial Fibrillation (NVAF) patients, who used apixaban as a secondary stroke/TIA prevention.